Jaguar Health, Inc. (JAGX) Stock Score, Valuation & Financial Research
Jaguar Health, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for JAGX
Jaguar Health, Inc. currently has a Wall Street Score of 15/100. The stored market price is $0.26. Its financial score is 1/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Jaguar Health, Inc. does
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients s
JAGX financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $0.26
- Market capitalization:
- $17K
- Revenue:
- $29.6M
- Net income:
- $-34.1M
- Free cash flow:
- $5.8M
- Cash:
- $7.3M
- Total debt:
- $43.8M
- EPS:
- -803.95
- Financial score:
- 1/100
- Valuation score:
- 0/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is +1.6%.
- Free cash flow is $5.8M, showing positive cash generation.
- The balance sheet shows $7.3M of cash versus $43.8M of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 1/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research JAGX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.